Search research articles
Contact Us
Filters
Showing results (381-390 of 483) with videos related to
Page
of 49
Sort By:
The New England Journal of Medicine
|
March 18, 2008
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
Marc E Rothenberg, Amy D Klion, Florence E Roufosse, et al.
Research Square
|
June 5, 2025
Multi-trait Analysis of GWAS Expands Eosinophilic Esophagitis Genetic Susceptibility and Polygenic Risk Scores
Michael P Trimarchi, Bahram Namjou-Khales, Netali Ben-Baruch Morgenstern, et al.
The Journal of Allergy and Clinical Immunology
|
June 9, 2015
Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease
Lisa J Martin, James P Franciosi, Margaret H Collins, et al.
Frontiers in Genetics
|
December 6, 2014
Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis
Bahram Namjou, Keith Marsolo, Robert J Caroll, et al.
The Journal of Allergy and Clinical Immunology
|
October 9, 2012
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Florence E Roufosse, Jean-Emmanuel Kahn, Gerald J Gleich, et al.
The Journal of Allergy and Clinical Immunology
|
January 30, 2014
Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities
Jonathan J Lyons, Guangping Sun, Kelly D Stone, et al.
Science Translational Medicine
|
May 29, 2020
Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis
Nurit P Azouz, Andrea M Klingler, Purnima Pathre, et al.
The Lancet. Gastroenterology & Hepatology
|
September 3, 2023
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marc E Rothenberg, Evan S Dellon, Margaret H Collins, et al.
The Journal of Allergy and Clinical Immunology
|
December 26, 2021
Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field
Marc E Rothenberg, Shawna K B Hottinger, Nirmala Gonsalves, et al.
The Journal of Allergy and Clinical Immunology
|
April 24, 2013
High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders
J Pablo Abonia, Ting Wen, Emily M Stucke, et al.
Page
of 49
Search research articles
Search
Showing results (381-390 of 483) with videos related to
Sort By:
Page
of 49
The New England Journal of Medicine
|
March 18, 2008
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
Marc E Rothenberg, Amy D Klion, Florence E Roufosse, et al.
Research Square
|
June 5, 2025
Multi-trait Analysis of GWAS Expands Eosinophilic Esophagitis Genetic Susceptibility and Polygenic Risk Scores
Michael P Trimarchi, Bahram Namjou-Khales, Netali Ben-Baruch Morgenstern, et al.
The Journal of Allergy and Clinical Immunology
|
June 9, 2015
Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease
Lisa J Martin, James P Franciosi, Margaret H Collins, et al.
Frontiers in Genetics
|
December 6, 2014
Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis
Bahram Namjou, Keith Marsolo, Robert J Caroll, et al.
The Journal of Allergy and Clinical Immunology
|
October 9, 2012
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Florence E Roufosse, Jean-Emmanuel Kahn, Gerald J Gleich, et al.
The Journal of Allergy and Clinical Immunology
|
January 30, 2014
Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities
Jonathan J Lyons, Guangping Sun, Kelly D Stone, et al.
Science Translational Medicine
|
May 29, 2020
Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis
Nurit P Azouz, Andrea M Klingler, Purnima Pathre, et al.
The Lancet. Gastroenterology & Hepatology
|
September 3, 2023
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marc E Rothenberg, Evan S Dellon, Margaret H Collins, et al.
The Journal of Allergy and Clinical Immunology
|
December 26, 2021
Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field
Marc E Rothenberg, Shawna K B Hottinger, Nirmala Gonsalves, et al.
The Journal of Allergy and Clinical Immunology
|
April 24, 2013
High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders
J Pablo Abonia, Ting Wen, Emily M Stucke, et al.
Page
of 49